The Week Ahead: Fed...
Health Care: Drugs
Arrowhead Research Corporation (ARWR: NASDAQ)
$3.85 -0.08 | -2.04%
06/04/12 - 10:57 AM ET
Company Income Statement
| Sep 2011 | Sep 2010 | Sep 2009 | Sep 2008 | |
| Sales | 296.14K | 620.10K | 3.77M | 1.30M |
| Cost of Sales | -18.23K | -339.06K | -607.51K | -722.97K |
| Gross Operating Profit | 314.37K | 959.16K | 4.38M | 2.03M |
| Selling, General, and Administrative Expenses | 5.23M | 8.00M | 14.14M | 23.75M |
| Research & Development | 3.28M | 1.11M | 8.97M | 12.14M |
| Operating Income before D & A (EBITDA) | -8.19M | -8.15M | -18.73M | -33.87M |
| Depreciation & Amortization | 260.04K | 654.69K | 994.60K | 1.13M |
| Interest Income | 86.53K | 0.00 | 0.00 | 736.34K |
| Other Income - Net | -255.01K | 1.69M | 96.88K | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -8.79M | -7.34M | -19.16M | -34.38M |
| Interest Expense | 0.00 | 48.02K | 150.89K | 0.00 |
| Pre-Tax Income | -8.79M | -7.38M | -19.31M | -34.38M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | -363.51K | -1.18M | -60.00 | -7.45M |
| Net Income From Continuing Operations | -8.79M | -7.38M | -19.31M | -26.94M |
| Net Income From Discontinued Operations | 5.29M | 427.34K | 0.00 | -153.60K |
| Net Income From Total Operations | -3.49M | -6.96M | -19.31M | -27.09M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -3.13M | -5.77M | -19.31M | -27.09M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-8.79M | -7.38M | -19.31M | -26.94M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -8.79M | -7.38M | -19.31M | -26.94M |
| Basic EPS from Continuing Ops. | -1.18 | -1.00 | -4.30 | -6.90 |
| Basic EPS from Discontinued Ops. | 0.74 | 0.10 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.44 | -0.90 | -4.30 | -6.90 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.44 | -0.90 | -4.30 | -6.90 |
| Basic Normalized Net Income/Share | -1.18 | -1.00 | -4.30 | -6.90 |
| EPS fr Continuing Ops. | -1.08 | -1.00 | -4.30 | -6.90 |
| EPS fr Discontinued Ops | 0.68 | 0.10 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.40 | -0.90 | -4.30 | -6.90 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.40 | -0.90 | -4.30 | -6.90 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.08 | -1.00 | -4.30 | -6.90 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ARWR
- Portfolio NameUser Type
- UserKJP 2012 Carbon Flash Fund
- Contributor8 Penny Stocks Get Delistin...
- UserWilliam T Blanchard - Medical
- UserCaroline
- UserSimon $9000
- Usertreneehill's pennies
- Userpeaka22 Portfolio 1
- Userkevin sweeney Portfolio 1
- UserWORLD FREE
- Userkeyon communications
Latest ARWR Headlines from TheStreet
- Arrowhead Research's CEO Hosts Alvos Acquisition Conference Call (Transcript) 05.08.12 | 12:05 am
- 6 Stocks Hitting New 52-Week Highs 11.10.11 | 01:11 pm
- 8 Penny Stocks Get Delisting Warning 01.04.11 | 07:01 am
- Arrowhead Research CEO Discusses F4Q2010 Results  Earnings Call Transcript 12.22.10 | 09:12 pm
- Arrowhead Research Corp. F3Q10 (Qtr End 06/30/10) Earnings Call Transcript 08.12.10 | 06:08 pm
- Mediacom, Jones Soda: Midday Volume Plays 06.01.10 | 10:06 am
- Arrowhead Research, Verenium: Early Volume Plays 03.22.10 | 07:03 am
- Amicas, Limelight: Early Volume Plays 12.28.09 | 07:12 am
- Thursday's Small-Cap Winners & Losers 06.20.07 | 01:06 am
- Friday's ETF Winners & Losers 06.20.07 | 01:06 am
Press Releases for ARWR
- Arrowhead Presents Data On DPC System At TIDES 2012 - Business Wire 05.22.12 | 07:05 am
- Arrowhead Reports Fiscal 2012 Second Quarter Financial Results - Business Wire 05.08.12 | 04:05 pm
- Arrowhead Research Corporation Acquires Alvos Therapeutics And Proprietary Library Of Targeting Peptides - Business Wire 04.11.12 | 07:04 am
- Arrowhead Releases White Paper On Hepatitis B Virus And Potential RNAi Treatment - Business Wire 03.07.12 | 07:03 am
- Arrowhead Research Corporation And Axolabs GmbH Enter Into Strategic Alliance And Master Services Agreement For RNAi Therapeutics - Business Wire 03.05.12 | 07:03 am
- Arrowhead Announces Patent Issuance Covering SiRNA Inhibitors Of HIF-2α (EPAS1) - Business Wire 02.29.12 | 07:02 am
- Arrowhead Reports Fiscal 2012 First Quarter Financial Results - Business Wire 02.09.12 | 04:02 pm
- Arrowhead To Report Fiscal 2012 First Quarter Financial Results - Business Wire 02.02.12 | 07:02 am
- Alnylam And Arrowhead Form Collaboration And Licensing Agreement - Business Wire 01.05.12 | 08:01 am
- Arrowhead Announces FDA Clearance To Initiate AdipotideTM Phase I Clinical Trial - Business Wire 01.04.12 | 07:01 am
Partner Headlines for ARWR
- 4 Smaller Alternatives to Big Pharma Obesity Treatments - Benzinga 05.25.12 | 01:05 pm
- Tekmira: RNAi Company With Long Term Potential, Short Term Catalysts - Seeking Alpha 03.07.12 | 08:03 am
- Arrowhead Reports Q1 EPS of $(0.02) - Benzinga 02.10.11 | 04:02 pm
- UPDATE 1-Arrowhead co, Smith & Nephew to make cartilage product - Reuters 10.18.10 | 08:10 am
